Authors' reply  by Sipahioglu, Serkan
ble at ScienceDirect
Acta Orthopaedica et Traumatologica Turcica 50 (2016) 708Contents lists availaActa Orthopaedica et Traumatologica Turcica
journal homepage: https: / /www.elsevier .com/locate/aottAuthors' reply
Serkan Sipahioglu
Harran University, Sanliurfa, Turkeya r t i c l e i n f oArticle history:
Available online 10 November 2016Thank you for your interest in our paper entitled, “Effect of
salmon calcitonin treatment on serum and synovial ﬂuid bone
formation and resorptionmarkers in osteoporosis patients”.1 In this
study, we aimed to identify more speciﬁc parameters for osteopo-
rosis diagnosis and osteoporosis treatment effectivity in relation to
synovial ﬂuid and to reveal the relationship between joint cartilage
and osteoporosis. Apart from osteoporosis, as determined by bone
resorption and formation products in synovial ﬂuid, these results
can also be interpreted for the evaluation of osteolytic activity in
the joint which is signiﬁcant for implant osteolysis. In osteoporosis,
increased activity of receptor activator of nuclear factor kappa B
ligand (RANKL) relative to its inhibitor osteoprotegerin in bone
tissue which results in increased osteoclastic activity and bone
resorption is a known issue.2 Particle induced bone osteolysis
which is a serious problem in implant loosening results from
increased RANKL activity in the periimplant tissue which shows
increased osteoclastic activity.3 Therefore, increased bone resorp-
tion marker levels in synovial ﬂuid can be expected in aseptic
loosening caused by particle induced bone osteolysis, and our study
can be a control group as for determination of bone resorption
markers in the synovial ﬂuid. Several studies have suggested that
increased subchondral bone turnover is a determinant of progres-
sion of osteoarthritis similar to osteoporosis.4 Disease progression
can be followed by changes in the levels of bone resorption marker
levels in the urine. More speciﬁcally bone resorption markers can
be determined in the synovial ﬂuid of the where osteoarthritis is
progressively seen. A recent study has shown that high levels of
bone resorption markers measured early in rheumatoid arthritis
patients, predicted an increased risk of further articular damage.5E-mail address: drserkans@gmail.com.
http://dx.doi.org/10.1016/j.aott.2015.11.002
1017-995X/© 2016 Turkish Association of Orthopaedics and Traumatology. Publishing se
(http://creativecommons.org/licenses/by-nc-nd/4.0/).However bone formation and resorption marker evaluation in
these designated inﬂammatory diseases (osteoarthritis, rheuma-
toid arthritis, aseptic loosening) is more appropriate for following
disease progression. Mechanisms that results in bone and cartilage
metabolism should be detected as for preventing disease progres-
sion. It has been shown that bone resorption might related to A
Disintegrin-like and Metalloproteinase with Thrombospondin type
1 Motifs (ADAMTS) enzyme activation/inhibition pathways.6 In
addition, while radiological measurements like bone mineral
density provides local and static information only about the
measured region, measurement of biochemical markers provides
both systemic and dynamic results. So it determines the need for
initiating treatment before radiological changes occur and also can
be used for treatment adherence.7 In addition, drugs targeting key
molecules that are related to disease pathogenesis would be
beneﬁcial in improving symptoms or slowing disease progression.References
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